How can high-throughput screening deliver drugs to treat atherosclerosis?

Expert Opinion on Drug Discovery

Volumn 5, Issue 12, 2010, Pages 1175-1188

  Yang, Yuan ^a,b   Wang, Li ^a   Si, Shuyi ^a   Hong, Bin ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

atherosclerosis; drug discovery; drug targets; foam cell formation; HDL cholesterol; HTS; LDL cholesterol; lipid lowering drugs; RCT

Indexed keywords

AEGR 773; ATORVASTATIN; AVE 5530; BEAUVERIOLIDE I; BEAUVERIOLIDE III; BMS 201038; CP 346086; ER 27856; EZETIMIBE; GW 532; HYPOCHOLESTEROLEMIC AGENT; LXR 623; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; PENTACECILIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIPERINE; PLACEBO; QUINAZOLINE DERIVATIVE; ROSMARINIC ACID; RPR 107393; RUBIMAILLIN; RVX 208; SALVIONOLIC ACID B; SLX 4090; SODIUM DANSHENSU; SQUALENE SYNTHASE INHIBITOR; TAK 475; TRIACSIN C; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 53601;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSLCEROSIS; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DRUG SAFETY; DRUG SCREENING; FOAM CELL; HEPATITIS; HIGH THROUGHPUT SCREENING; HUMAN; LIPID ABSORPTION; LIPOPROTEIN METABOLISM; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET CELL; UPREGULATION;

EID: 78649349303     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.529896     Document Type: Review

References (103)

1. Toutouzas K, Drakopoulou M, Skoumas I, et al. Advancing therapy for hypercholesterolemia. Expert Opin Pharmacother 2010;11:1659-72
2. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376
3. Pearson T, Ballantyne C, Sisk C, et al. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 2007;99:1706-13
4. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J 2008;84:590-8
5. Khera AV, Rader DJ. Future therapeutic directions in reverse cholesterol transport. Curr Atheroscler Rep 2010;12:73-81
6. Smith EB. The relationship between plasma and tissue lipids in human atherosclerosis. Adv Lipid Res 1974;12:1-49
7. Libby P. Atherosclerosis: the new view. Sci Am 2002;286:46-55
8. Olofsson SO, Asp L, Boren J. The assembly and secretion of apolipoprotein B-containing lipoproteins. Curr Opin Lipidol 1999;10:341-6
9. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-4
10. Dhaliwal BS, Steinbrecher UP. Scavenger receptors and oxidized low density lipoproteins. Clin Chim Acta 1999;286:191-205
11. Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002;277:49982-8
12. Moore KJ, Kunjathoor VV, Koehn SL, et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest 2005;115:2192-201
13. Kuchibhotla S, Vanegas D, Kennedy DJ, et al. Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc Res 2008;78:185-96
14. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975;1:16-9
15. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
16. Do R, Kiss RS, Gaudet D, et al. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. Clin Genet 2009;75:19-29
17. Tait RM. Development of a radiometric spot-wash assay for squalene synthase. Anal Biochem 1992;203:310-16
18. Baxter A, Fitzgerald BJ, Hutson JL, et al. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J Biol Chem 1992;267:11705-8
19. Amin D, Rutledge RZ, Needle SN, et al. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther 1997;281:746-52
20. Hiyoshi H, Yanagimachi M, Ito M, et al. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors. J Lipid Res 2000;41:1136-44
21. Ugawa T, Kakuta H, Moritani H, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol 2000;131:63-70
22. Grand-Perret T, Bouillot A, Perrot A, et al. SCAP ligands are potent new lipid-lowering drugs. Nat Med 2001;7:1332-8
23. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344-51
24. Abidi P, Zhou Y, Jiang JD, et al. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005;25:2170-6
25. Lee S, Lim HJ, Park HY, et al. Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model. Atherosclerosis 2006;186:29-37
26. Lee S, Lim HJ, Park JH, et al. Berberine-induced LDLR up-regulation involves JNK pathway. Biochem Biophys Res Commun 2007;362:853-7
27. Liang KW, Ting CT, Yin SC, et al. Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem Pharmacol 2006;71:806-17
28. Brusq JM, Ancellin N, Grondin P, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006;47:1281-8
29. Tang LQ, Wei W, Chen LM, et al. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol 2006;108:109-15
30. Cicero AF, Rovati LC, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung 2007;57:26-30
31. Yin J, Zhang H, Ye J. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008;8:99-111
32. Li YH, Yang P, Kong WJ, et al. Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy. J Med Chem 2009;52:492-501
33. Li YH, Li Y, Yang P, et al. Design, synthesis, and cholesterol-lowering efficacy for prodrugs of berberrubine. Bioorg Med Chem 2010;18:6422-8
34. Yang P, Song DQ, Li YH, et al. Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators. Bioorg Med Chem Lett 2008;18:4675-7
35. Wang YX, Wang YP, Zhang H, et al. Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor. Bioorg Med Chem Lett 2009;19:6004-8
36. Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem 2004;47:1-9
37. Yu L, Bharadwaj S, Brown JM, et al. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J Biol Chem 2006;281:6616-24
38. Ge L, Wang J, Qi W, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab 2008;7:508-19
39. ClincialTrials. gov: Evaluation of efficacy and safety of AVE5530 co-administered with atorvastatin in primary hypercholesterolemia. Available from: http://clinicaltrialsgov/ct2/show/
40. NCT00741715?term=AVE5530&rank=3">http://clinicaltrialsgov/ ct2/show/NCT00741715?term=AVE5530&rank=3 [Last acessed 10 November 2009]
41. Hussain MM, Iqbal J, Anwar K, et al. Microsomal triglyceride transfer protein: a multifunctional protein. Front Biosci 2003;8:s500-6
42. Raabe M, Veniant MM, Sullivan MA, et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest 1999;103:1287-98
43. Chandler CE, Wilder DE, Pettini JL, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003;44:1887-901
44. Haghpassand M, Wilder D, Moberly JB. Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (HepG2). J Lipid Res 1996;37:1468-80
45. Sweetnam P, Kim E, Yand YF, et al. SLx: a novel, intestinal-specific MTP inhibitor for lowering plasma triglyceride and cholesterol levels in dyslipidemia. Am J Gastroenterol 2010;100:100-1
46. Namatame I, Tomoda H, Arai H, et al. Complete inhibition of mouse macrophage-derived foam cell formation by triacsin C. J Biochem 1999;125:319-27
47. Namatame I, Tomoda H, Ishibashi S, et al. Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages. Proc Natl Acad Sci USA 2004;101:737-42
48. Yamazaki H, Omura S, Tomoda H. Pentacecilides, new inhibitors of lipid droplet formation in mouse macrophages produced by Penicillium cecidicola FKI-3765-1: II. Structure elucidation. J Antibiot (Tokyo) 2009;62:207-11
49. Matsuda D, Ohte S, Ohshiro T, et al. Molecular target of piperine in the inhibition of lipid droplet accumulation in macrophages. Biol Pharm Bull 2008;31:1063-6
50. Matsuda D, Ohshiro T, Ohba M, et al. The molecular target of rubimaillin in the inhibition of lipid droplet accumulation in macrophages. Biol Pharm Bull 2009;32:1317-20
51. Matsuda D, Namatame I, Ohshiro T, et al. Anti-atherosclerotic activity of triacsin C, an acyl-CoA synthetase inhibitor. J Antibiot (Tokyo) 2008;61:318-21
52. Etzion Y, Hackett A, Proctor BM, et al. An unbiased chemical biology screen identifies agents that modulate uptake of oxidized LDL by macrophages. Circ Res 2009;105:148-57
53. Nicholson AC, Frieda S, Pearce A, et al. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol 1995;15:269-75
54. Nozaki S, Kashiwagi H, Yamashita S, et al. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest 1995;96:1859-65
55. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000;105:1049-56
56. Guy E, Kuchibhotla S, Silverstein R, et al. Continued inhibition of atherosclerotic lesion development in long term Western diet fed CD36o/apoEo mice. Atherosclerosis 2007;192:123-30
57. Wang L, Bao Y, Yang Y, et al. Discovery of antagonists for human scavenger receptor CD36 via an ELISA-like high-throughput screening assay. J Biomol Screen 2010;15:239-50
58. Xu Y, Wang J, Bao Y, et al. Identification of two antagonists of the scavenger receptor CD36 using a high-throughput screening model. Anal Biochem 2010;400:207-12
59. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007;117:2216-24
60. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999;22:336-45
61. Gao J, Xu Y, Yang Y, et al. Identification of upregulators of human ATP-binding cassette transporter A1 via high-throughput screening of a synthetic and natural compound library. J Biomol Screen 2008;13:648-56
62. Schmitz G, Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim Biophys Acta 2005;1735:1-19
63. Bultel S, Helin L, Clavey V, et al. Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages. Arterioscler Thromb Vasc Biol 2008;28:2288-95
64. Naik SU, Wang X, Da Silva JS, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006;113:90-7
65. Li AC, Glass CK. PPAR-and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 2004;45:2161-73
66. Katz A, Udata C, Ott E, et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol 2009;49:643-9
67. Molteni V, Li X, Nabakka J, et al. N-acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta. J Med Chem 2007;50:4255-9
68. Chin J, Adams AD, Bouffard A, et al. Miniaturization of cell-based beta-lactamase-dependent FRET assays to ultra-high throughput formats to identify agonists of human liver X receptors. Assay Drug Dev Technol 2003;1:777-87
69. Zhang Y, Zanotti I, Reilly MP, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003;108:661-3
70. Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 2010;55:2580-9
71. Deng T, Ji W, Lian J, et al. Identifying natural derived upregulators of human ApoA-I expression via a cell-based drug screening system. Pharm Biol 2008;46:610-15
72. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93
73. Millar JS, Duffy D, Gadi R, et al. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol 2009;29:140-6
74. Seethala R, Golla R, Ma Z, et al. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator. Anal Biochem 2007;363:263-74
75. Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374:126-35
76. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-7
77. McKenney JM, Davidson MH, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006;48:1782-90
78. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7
79. Rittershaus CW, Miller DP, Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2106-12
80. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
81. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
82. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
83. Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol 2009;104:32E-38E
84. Sviridov D, Mukhamedova N, Remaley AT, et al. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 2008;15:52-62
85. Rano TA, Sieber-McMaster E, Pelton PD, et al. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Bioorg Med Chem Lett 2009;19:2456-60
86. Kuo GH, Rano T, Pelton P, et al. Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5- [3-(trif luoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor. J Med Chem 2009;52:1768-72
87. Eveland SS, Milot DP, Guo Q, et al. A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology. Anal Biochem 2007;368:239-49
88. Smith CJ, Ali A, Chen L, et al. 2-Arylbenzoxazoles as CETP inhibitors: substitution of the benzoxazole moiety. Bioorg Med Chem Lett 2010;20:346-9
89. Maugeais C, Tietge UJ, Broedl UC, et al. Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation 2003;108:2121-6
90. Jin W, Millar JS, Broedl U, et al. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest 2003;111:357-62
91. Badellino KO, Wolfe ML, Reilly MP, et al. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med 2006;3:e22
92. Keller PM, Rust T, Murphy DJ, et al. A high-throughput screen for endothelial lipase using HDL as substrate. J Biomol Screen 2008;13:468-75
93. Goodman KB, Bury MJ, Cheung M, et al. Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. Bioorg Med Chem Lett 2009;19:27-30
94. Acton S, Rigotti A, Landschulz KT, et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996;271:518-20
95. Calvo D, Dopazo J, Vega MA. The CD36, CLA-1 (CD36L1), and LIMPII (CD36L2) gene family: cellular distribution, chromosomal location, and genetic evolution. Genomics 1995;25:100-6
96. Cao G, Garcia CK, Wyne KL, et al. Structure and localization of the human gene encoding SR-BI/CLA-1. Evidence for transcriptional control by steroidogenic factor 1. J Biol Chem 1997;272:33068-76
97. Ji Y, Jian B, Wang N, et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997;272:20982-5
98. Acton SL, Kozarsky KF, Rigotti A. The HDL receptor SR-BI: a new therapeutic target for atherosclerosis? Mol Med Today 1999;5:518-24
99. Yang Y, Zhang Z, Jiang W, et al. Identification of novel human high-density lipoprotein receptor up-regulators using a cell-based high-throughput screening assay. J Biomol Screen 2007;12:211-19
100. Bao Y, Yang Y, Wang L, et al. Identification of trichostatin A as a novel transcriptional up-regulator of scavenger receptor BI both in HepG2 and RAW 264.7 cells. Atherosclerosis 2009;204:127-35
101. Steinberg D. The statins in preventive cardiology. N Engl J Med 2008;359:1426-7
102. Fox S, Farr-Jones S, Sopchak L, et al. High-throughput screening: update on practices and success. J Biomol Screen 2006;11:864-9
103. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-77